Cargando…
COVID-19 and Diarylamidines: The Parasitic Connection
As emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants (Omicron) continue to outpace and negate combinatorial vaccines and monoclonal antibody therapies targeting the spike protein (S) receptor binding domain (RBD), the appetite for developing similar COVID-19 treatments h...
Autor principal: | Hulme, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094973/ https://www.ncbi.nlm.nih.gov/pubmed/37047556 http://dx.doi.org/10.3390/ijms24076583 |
Ejemplares similares
-
Mechanisms of NMDA Receptor Inhibition by Sepimostat—Comparison with Nafamostat and Diarylamidine Compounds
por: Zhigulin, Arseniy S., et al.
Publicado: (2023) -
Prescribing Phones to Address Health Equity Needs in the COVID-19 Era: The PHONE-CONNECT Program
por: Kazevman, Gill, et al.
Publicado: (2021) -
Plastid–endomembrane connections in apicomplexan parasites
por: Boucher, Michael J., et al.
Publicado: (2019) -
Autoimmunity and COVID-19 – The microbiotal connection
por: Katz-Agranov, Nurit, et al.
Publicado: (2021) -
Can anti-parasitic drugs help control COVID-19?
por: Panahi, Yasin, et al.
Publicado: (2022)